Invivyd, Inc. (IVVD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.62
- As of
Kresmion compiles this page from IVVD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Invivyd, Inc. (IVVD): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full IVVD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IVVD on one page. Preview it with sample data, then open it live with a free account.
Preview the IVVD dossierActive events for IVVD
- high13F: funds added
4 tracked funds increased IVVD this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 28.7%, EPS $-0.14 vs $-0.1088 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +224% to IVVD (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +7208% to IVVD (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +17068% to IVVD (2026Q2)
FREE, NO ACCOUNT
Every event on IVVD, as it fires
You are seeing 5 of 12 events recorded on IVVD since 2026-05-31.
The five above landed across 3 days. The other 7 were recorded on 2 other days. 6 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IVVD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 00534A102 · 2026Q2 | $6.6M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 00534A102 · 2026Q2 | $3.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00534A102 · 2026Q2 | $2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00534A102 · 2026Q2 | $1.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00534A102 · 2026Q2 | $868K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IVVD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IVVD against its peers
IVVD's operating margin of -104.0% ranks in the 79th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IVVD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 53.4M USD | 13.4M USD | 82 | 18 |
| Gross margin | n/a | 67.2% | n/a | 9 |
| Operating margin | -104.0% | -604.5% | 79 | 20 |
| Net margin | -98.2% | -276.7% | 69 | 20 |
| Return on equity | -21.7% | -49.7% | 72 | 22 |
Peers (24): ACOG, XGN, PRQR, WHWK, DTIL, CGEN, KRRO, ELDN, RNAC, YARW, PEPG, ORMP, TRDA, EVMN, NAGE, SION, IPHA, PYXS, ADAG, ALXO, ALEC, PLX, CAMP, CHRS. Left out: SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IVVD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IVVD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IVVD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.